{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-075268","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.022460+00:00","generated_at":"2026-05-17T17:22:32.928554+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cognition Therapeutics Q2 net loss $6.7M; cash runway into Q2 2026; clinical milestones","bullets":["Net loss of $6.7M ($0.11 per share) vs. $7.0M ($0.18 per share) in Q2 2024.","Cash and equivalents $11.6M; plus $41.9M in NIA grant funds; runway into Q2 2026.","Surpassed 50% enrollment in Phase 2 START study of zervimesine in early Alzheimer's.","EOP2 meeting with FDA held; breakthrough designation application for zervimesine in DLB pending.","Positive Phase 2 dry AMD data showed 28.6% reduction in GA lesion growth at 18 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-075268","json":"https://secwatch.observer/filing/0001104659-25-075268.json","markdown":"https://secwatch.observer/filing/0001104659-25-075268.md","text":"https://secwatch.observer/filing/0001104659-25-075268.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465925075268/0001104659-25-075268-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465925075268/tm2522152d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:22:32.928554+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}